The latest report by the World Health Organization on HIV drug resistance provided an in-depth look on the growth of the resistance to HIV medications. It also covered the steps countries are taking to ensure people receive effective medicine to treat people with HIV.
The report disclosed that in 2020, 64% of the countries with a high HIV burden had action plans to prevent, monitor, and respond to HIV drug resistance. WHO also stated that an increasing number of countries reached a 10% threshold of pre-treatment drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTI).
The report mentioned that people who had previous exposure to antiretroviral drugs are three times more likely to demonstrate resistance to the NNRTI drug class. The findings emphasized that there’s a need to accelerate the transition to dolutegravir-containing regimens in countries that continue to use NNRTI-based antiretrovirals to prevent resistance.
Furthermore, the report disclosed that the number of countries achieving high levels of viral suppression increased from 33% in 2017 to 80% in 2020. WHO noted that attaining high levels of viral load suppression in populations taking antiretroviral therapy prevents transmission of HIV, HIV-associated morbidity and mortality, and prevents the emergence of HIV drug resistance.
Currently, the best prevention option for HIV-negative people at risk of HIV infection is pre-exposure prophylaxis (PrEP). PrEP drugs like Truvada have recorded a lot of success, but they have also seen a lot of complaints from users. These complainants have turned into lawsuits against the manufacturers with the plaintiffs demanding compensation for the illnesses caused by the drug.
Before filing a claim, a person must first ascertain that they have a valid cause of action. A mass tort lawyer at Dalimonte Rueb Stoller LLP can help you decide your eligibility for compensation. Contact us today.